<DOC>
	<DOCNO>NCT02633137</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , treatment include 1 ) Lenalidomide-RCHOP , 2 ) R-HIDAC , 3 ) Lenalidomide-Rituximab maintenance participant lymphoma .</brief_summary>
	<brief_title>Sequential Chemotherapy Lenalidomide Followed Rituximab Lenalidomide Maintenance Untreated Mantle Cell Lymphoma</brief_title>
	<detailed_description>Patients receive lenalidomide 15 mg orally daily day 1-14 standard-dose R-CHOP ( 375 mg/m^2 intravenous rituximab , 750 mg/m2 intravenous cyclophosphamide , 50 mg/m^2 intravenous doxorubicin , 1.4 mg/m2 intravenous vincristine day 1 , 100 mg prednisone day 1-5 day 2-6 ) every 21 day four cycle . All patient receive pegfilgrastim day 2 cycle aspirin 81 mg orally daily venous thromboembolism prophylaxis throughout four cycle . After four cycle Len-RCHOP , patient undergo restaging PET/CT scan . Patients evidence disease progression treat study . R-HIDAC After lenalidomide-RCHOP phase , patient without evidence progressive disease receive rituximab 375 mg/m^2 day 1 patient admit high-dose cytarabine ( HIDAC ) . Recommended age-adjusted HIDAC dose follow : ≤65 year : 3 g/m2 every12 hour X 4 dos ; 65-70 year : 2 g/m^2 every12 hour X 4 dos ; &gt; 70 year : 1 g/m^2 every12 hour X 4 dos . Physician discretion dictate choice HIDAC dose , range 1 g/m^2 - 3 g/m^2 every 12 hour X 4 dos . Patients receive two cycle rituximab-HIDAC every 3 week . After two cycle R-HIDAC , patient undergo restaging PET/CT scan . Patients evidence disease progression treat study . Len-Rituximab Maintenance After completion induction chemotherapy Len-RCHOP R-HIDAC , patient begin maintenance phase lenalidomide rituximab 6 month . Lenalidomide administer 15 mg orally daily day 1-21 28-day cycle total 6 cycle rituximab maintenance every 8 week total 3 treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Previously untreated mantle cell lymphoma patient ( least clinical stage 2 ) Histologic diagnosis confirm MSKCC pathologist mantle cell lymphoma Presence evaluable disease Age ≥18 year KPS ≥ 70 % Adequate organ function : ANC ≥1500 platelet count ≥100,000 , unless felt secondary underlying mantle cell lymphoma Renal function assess calculated creatinine clearance follow : CockcroftGault estimation CrCl ) : Calculated creatinine clearance ≥ 30ml/min CockcroftGault formula . See section , `` Dosing Regimen '' , regard lenalidomide dose adjustment calculate creatinine clearance ≥30ml/min &lt; 60ml/min . Adequate hepatic function determine Total bilirubin &lt; 1.5X upper limit normal ( ULN ) ( unless know Gilbert syndrome ) AST ( SGOT ) ALT ( SGPT ) 3 x ULN All study participant must register mandatory Revlimid REMS® program , willing able comply requirement REMS® program . Females reproductive potential must adhere scheduled pregnancy test require Revlimid REMS® program . Each subject must sign informed consent form indicate understand purpose procedure require study willing participate . Short course systemic corticosteroid permissible disease control , improvement performance status noncancer indication ≤ 10 day must discontinue prior study treatment . Known central nervous system ( CNS ) lymphoma Uncontrolled severe cardiovascular disease leave ventricular ejection fraction &lt; 50 % determine echocardiogram MUGA . Any lifethreatening illness , medical condition , organ system dysfunction , investigator 's opinion , could compromise subject 's safety put study outcome undue risk . Pregnant breastfeeding . Premenopausal patient must negative serum HCG within 14 day enrollment . Patients use ≥20 mg/day prednisone ( steroid equivalent dose ) chronic medical condition Known seropositive , require antiviral therapy , detectable viral load PCR human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Known hypersensitivity thalidomide lenalidomide The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Patients plan upfront consolidation highdose therapy autologous stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>15-196</keyword>
</DOC>